| scholarly article | Q13442814 |
| P2093 | author name string | T. DOBZHANSKY | |
| P2860 | cites work | Genetic Variability, Twin Hybrids and Constant Hybrids, in a Case of Balanced Lethal Factors. | Q24531957 |
| The Effect of Selection for Eye Facet Number in the White Bar-Eye Race of DROSOPHILA MELANOGASTER. | Q33944519 | ||
| Iso-Alleles at the Bobbed Locus in Drosophila Hydei Populations | Q33974439 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | genetic recombination | Q211675 |
| Drosophila | Q312154 | ||
| Drosophila pseudoobscura | Q1314678 | ||
| P1104 | number of pages | 22 | |
| P304 | page(s) | 269-290 | |
| P577 | publication date | 1946-05-01 | |
| P1433 | published in | Genetics | Q3100575 |
| P1476 | title | Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura | |
| P478 | volume | 31 |
| Q37313669 | A better way to discover gene function in the social amoeba Dictyostelium discoideum |
| Q33757656 | A defect in the acetyl coenzyme A<-->acetate pathway poisons recombinational repair-deficient mutants of Escherichia coli |
| Q27302763 | A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An |
| Q35537834 | A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells |
| Q34249365 | ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition |
| Q51662524 | An intermittent approach for cancer chemoprevention. |
| Q89953401 | Ataxia telangiectasia mutated (ATM), could it be another useful biomarker for the successful treatment with the poly (ADP-ribose) polymerase inhibitor? |
| Q37605747 | BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different |
| Q24630872 | BRCAness: finding the Achilles heel in ovarian cancer |
| Q33798999 | Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions |
| Q37705303 | Combinatorial strategies for combating invasive fungal infections. |
| Q33609650 | Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells |
| Q37761065 | Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science |
| Q52641490 | Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches. |
| Q89664244 | Designing minimal genomes using whole-cell models |
| Q34380368 | Development of synthetic lethality anticancer therapeutics |
| Q90103101 | Drosophila Model in Cancer: An Introduction |
| Q51220832 | Ecological aspects of the recombination problem. |
| Q38434114 | Epigenetic Medicinal Chemistry |
| Q37328845 | Epigenetic alterations in human prostate cancers. |
| Q40038745 | Exacerbating and reversing lysosomal storage diseases: from yeast to humans |
| Q33583509 | Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient |
| Q37597842 | Exploiting synthetic lethal interactions for targeted cancer therapy |
| Q27015719 | Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents |
| Q41345892 | Finding friends and enemies in an enemies-only network: a graph diffusion kernel for predicting novel genetic interactions and co-complex membership from yeast genetic interactions |
| Q27694529 | Fine tuning chemotherapy to match BRCA1 status |
| Q34439935 | Genetic interactions reveal the evolutionary trajectories of duplicate genes |
| Q92555567 | Global Genetic Networks and the Genotype-to-Phenotype Relationship |
| Q34828123 | Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota |
| Q37439146 | Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy |
| Q64994221 | Importance of genetic screens in precision oncology. |
| Q37285084 | Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells |
| Q37984197 | Inhibiting homologous recombination for cancer therapy |
| Q38826337 | Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells |
| Q41221199 | Intercellular Genetic Interaction Between Irf6 and Twist1 during Craniofacial Development |
| Q42569462 | JCVI-syn3.0 - A synthetic genome stripped bare! |
| Q34005003 | Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3 |
| Q34796394 | Link clustering reveals structural characteristics and biological contexts in signed molecular networks |
| Q37779240 | Making the best of PARP inhibitors in ovarian cancer |
| Q42153449 | Mapping the Synthetic Dosage Lethality Network of CDK1/CDC28. |
| Q38160737 | Mechanisms of resistance to therapies targeting BRCA-mutant cancers |
| Q28084988 | Mitonuclear Ecology |
| Q37847073 | Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies |
| Q39393193 | Molecularly targeted therapies for p53-mutant cancers |
| Q38756892 | New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors |
| Q35820721 | Nonrandom mating in Drosophila melanogaster laboratory populations derived from closely adjacent ecologically contrasting slopes at "Evolution Canyon". |
| Q27027014 | PARP inhibitors and more |
| Q89980735 | PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications |
| Q33941001 | Parallel universes of Black Six biology |
| Q91962793 | Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications |
| Q33669053 | Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer |
| Q36693272 | Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment |
| Q36595780 | Preventive evolutionary medicine of cancers |
| Q37698536 | Protein O-mannosylation in metazoan organisms |
| Q55314041 | Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery. |
| Q35620467 | Quantitative trait locus analysis of stage-specific inbreeding depression in the Pacific oyster Crassostrea gigas. |
| Q37950515 | Recent developments in treatment stratification for metastatic breast cancer |
| Q71680658 | Recessive genetic variants affecting mating activity of males in natural populations ofDrosophila melanogaster |
| Q38559892 | Regulation of recombination and genomic maintenance |
| Q38085600 | Resistance to PARP-Inhibitors in Cancer Therapy |
| Q36171193 | Role of PARP inhibitors in cancer biology and therapy |
| Q92578345 | SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines |
| Q39619627 | Sex to the rescue |
| Q47761787 | Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy |
| Q74123317 | Studies on female-sterility genes in Drosophila melanogaster. II. The effects of the gene fused on embryonic development |
| Q89187412 | Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls |
| Q55343692 | Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network. |
| Q37226478 | Synthetic genetic targeting of genome instability in cancer. |
| Q37801265 | Synthetic lethal approaches to breast cancer therapy |
| Q59793486 | Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast |
| Q38709651 | Synthetic lethality and cancer. |
| Q34671726 | Synthetic lethality between gene defects affecting a single non-essential molecular pathway with reversible steps |
| Q61809653 | Synthetic lethality guiding selection of drug combinations in ovarian cancer |
| Q28072904 | Synthetic lethality in lung cancer and translation to clinical therapies |
| Q35051154 | Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations |
| Q34151015 | Synthetic lethality: General principles, utility and detection using genetic screens in human cells |
| Q37442913 | Synthetic lethality: a framework for the development of wiser cancer therapeutics |
| Q33766729 | Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. |
| Q90707206 | Targeting DNA repair in cancer: current state and novel approaches |
| Q89496376 | Targeting dePARylation for cancer therapy |
| Q37977004 | The DNA damage response and cancer therapy |
| Q98771211 | The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer |
| Q39190147 | The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. |
| Q34214349 | The population genetics of X-autosome synthetic lethals and steriles |
| Q34539918 | The roles of whole-genome and small-scale duplications in the functional specialization of Saccharomyces cerevisiae genes. |
| Q37297075 | The unfolded protein response contributes to preimplantation mouse embryo death in the DDK syndrome |
| Q36429844 | Theodosius Dobzhansky on Hybrid Sterility and Speciation |
| Q26745673 | Trial watch - inhibiting PARP enzymes for anticancer therapy |
| Q38944795 | Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition. |
| Q24630038 | Yeast: an experimental organism for 21st Century biology |
| Q41227942 | dSLAM analysis of genome-wide genetic interactions in Saccharomyces cerevisiae |
Search more.